Evidence map›Paper›PMID 19017758›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2009

Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes.

Guillermo E Umpierrez, Tiffany Hor, Dawn Smiley, Angel Temponi, Denise Umpierrez, Miguel Ceron, Christina Munoz, Christopher Newton, Limin Peng, David Baldwin

6 registry-linked trialsOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 82 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 4 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00590226 phase4completednot on this map

Comparative Trial Between Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Type 2 Diabetes

TypeinterventionalSponsorEmory UniversityRan2006 to 2008Enrolled130ConditionsType 2 DiabetesArmsDetemir + aspart insulin before meals, NPH insulin + regular insulin
NCT00911625 phase4completednot on this map

Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

TypeinterventionalSponsorLoyola UniversityRan2009 to 2011Enrolled114ConditionsType 2 Diabetes, Renal InsufficiencyArms0.5 units/kg daily insulin, 0.25 units/kg daily insulin
NCT01136746 phase3terminatednot on this mapstarted 2011, after this paper: background citation

Randomized Clinical Trial of Subcutaneous Analog Basal Bolus Therapy Versus Sliding Scale Human Regular Insulin in the Hospital Management of Hyperglycemia in Non-Critically Ill Patients Without Known History of Diabetes: The HMH Trial

TypeinterventionalSponsorEli Lilly and CompanyRan2011 to 2011Enrolled16ConditionsHyperglycemiaArmsHuman regular insulin, Insulin lispro, Insulin glargine
NCT01855243 nacompletednot on this mapstarted 2010, after this paper: background citation

Premix 70/30 Insulin Plus Supplemental Lunch Insulin in Comparison to Basal Plus Prandial Supplemental Scale and Sliding Scale Insulin in Hospitalized Patients With Type 2 Diabetes

TypeinterventionalSponsorCairo UniversityRan2010 to 2014Enrolled63ConditionsDiabetes Mellitus (DM)Armsregular insulin, 70/30 insulin, Glargine, glulisine
NCT03455985 naterminatednot on this mapstarted 2018, after this paper: background citation

Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin

TypeinterventionalSponsorOhio State UniversityRan2018 to 2020Enrolled158ConditionsDiabetes Mellitus, Type 2, Patient Discharge, Blood Glucose, Low, Blood Glucose, HighArmsDischarge Order Set (DOS), Enhanced Standard Care (ESC)
NCT05036876 nacompletednot on this mapstarted 2021, after this paper: background citation

Insulin Degludec Versus Glargine U300 for the Management of Hospitalized Patients With Type 2 Diabetes: Randomized Controlled Trial

TypeinterventionalSponsorMedanta, The Medicity, IndiaRan2021 to 2022Enrolled220ConditionsType 2 DiabetesArmsDegludec, Glargine U300
3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 4 syntheses or guidelines pooled it, 177 citations in OpenAlex.

  1. [Hospital diabetes management (Update 2026)].Wiener klinische Wochenschrift · 2026
    Guideline
  2. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Guideline
  3. Pooled it
  4. Standards of medical care in diabetes--2010.Diabetes care · 2010 · on this map
    Guideline
  5. Randomized Study Comparing Continuous Glucose Monitoring and Capillary Glucose Testing in Patients With Type 2 Diabetes After Hospital Discharge.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Guillermo E UmpierrezDepartment of Medicine, Emory University, Atlanta, Georgia 30303, USA. geumpie@emory.edu
Tiffany Hor
Dawn Smiley
Angel Temponi
Denise Umpierrez
Miguel Ceron
Christina Munoz
Christopher Newton
Limin Peng
David Baldwin
Emory University · USRush University Medical Center · US

Funding

Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
X LINKED NYSTAGMUS SYNDROME WITH FEATURES OF ALBINISMM01RR000039 · NCRR · EMORY UNIVERSITY · PI VACCARINO, VIOLA · 1985 to 2007
$21.3M
Mentored Clinical Research Scholar ProgramK12RR017643 · NCRR · EMORY UNIVERSITY · PI BLUMBERG, HENRY M · 2002 to 2006
$5.1M
Markers of normoglycemic remission in obese diabeticsR03DK073190 · NIDDK · EMORY UNIVERSITY · PI UMPIERREZ, GUILLERMO E · 2005 to 2006
$237k
NCATS NIH HHS UL1 TR000454NCRR NIH HHS K12 RR-017643NCRR NIH HHS K12 RR017643NCRR NIH HHS M01 RR000039NCRR NIH HHS M01 RR-00039NIDDK NIH HHS R03 DK073190NIDDK NIH HHS R03 DK073190-01
6 · The paper itself

Abstract

backgroundStudies comparing the use of basal bolus with insulin analogs vs. split-mixed regimens with human insulins in hospitalized patients with type 2 diabetes are lacking. RESEARCH DESIGN AND

methodsIn a controlled multicenter trial, we randomized 130 nonsurgical patients with blood glucose (BG) between 140 and 400 mg/dl to receive detemir once daily and aspart before meals (n = 67) or neutral protamine Hagedorn (NPH) and regular insulin twice daily (n = 63). Insulin dose was started at 0.4 U/kg.d for BG between 140 and 200 mg/dl or 0.5 U/kg.d for BG 201-400 mg/dl. Major study outcomes included differences in mean daily BG levels and frequency of hypoglycemic events between treatment groups.

resultsGlycemic control improved similarly in both groups from a mean daily BG of 228 +/- 54 and 223 +/- 58 mg/dl (P = 0.61) to a mean daily BG level after the first day of 160 +/- 38 and 158 +/- 51 mg/dl in the detemir/aspart and NPH/regular insulin groups, respectively (P = 0.80). A BG target below 140 mg/dl before meals was achieved in 45% of patients in the detemir/aspart group and 48% in the NPH/regular group (P = 0.86). During treatment, 22 patients (32.8%) in the detemir/aspart group and 16 patients (25.4%) in the NPH/regular group had at least one episode of hypoglycemia (BG < 60 mg/dl) during the hospital stay (P = 0.34).

conclusionsTreatment with basal/bolus regimen with detemir once daily and aspart before meals results in equivalent glycemic control and no differences in the frequency of hypoglycemia compared to a split-mixed regimen of NPH and regular insulin in patients with type 2 diabetes.

Indexed as

InpatientsAdolescentAdultAgedAged, 80 and overDiabetes Mellitus, Type 2Drug Administration ScheduleFemaleHumansHypoglycemic AgentsInsulinInsulin AspartInsulin DetemirInsulin, IsophaneInsulin, Long-ActingMaleHypoglycemic AgentsInsulinInsulin AspartInsulin DetemirInsulin, IsophaneInsulin, Long-Acting

Identifiers

PMID19017758
PMCPMC2646523
OpenAlexW2022948195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.